International application No.

PCT/US04/38050

A. CLASSIFICATION OF SUBJECT MATTER							
IPC(7) : C12Q 1/68							
US CL: 435/6 According to International Patent Classification (IPC) or to both national classification and IPC							
B. FIELDS SEARCHED							
Minimum documentation searched (classification system followed by classification symbols) U.S.: 435/6							
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched							
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Please See Continuation Sheet							
C. DOCT	JMENTS CONSIDERED TO BE RELEVANT						
Category *	Citation of document, with indication, where a			Relevant to claim No.			
Y	US 2003/0171279 A1 (MUNGER et al) 11 Septemb	er 2003 (	(11.09.2003), see the claims	1-30			
Y	US 6,218,103 B1 (LEOPARDI et al) 17 April 2001 (17.04.2001), see the abstract.		1-30				
Y	MUNGER et al. The U(S)3 protein kinase blocks apoptosis induced by the d120 mutant of herpes simplex virus 1 at a premitochondrial stage. Journal of Virology. June 2001, Vol. 75, No. 12, pages 5491-5497, see the abstract.		1-30				
Y	MUNGER et al. The US3 protein kinase of herpes simplex virus 1 mediates the posttranslational modification of BAD and prevents BAD-induced programmed cell death in the absence of other viral proteins. Proc. Natl. Acad. Sci. USA 28 August 2001, Vol. 98, No. 18, pages 10410-1041, see the abstract.			1-30			
A GALVAN et al. Bcl-2 blocks a caspase-dependent pathway of apoptosis activated by herpes simplex virus 1 infection in HEp-2 cells.  Journal of Virology. February 2000, Vol. 74, No. 4, pages 1931-1938.			1-30				
Further	r documents are listed in the continuation of Box C.		See patent family annex.				
Special categories of cited documents:  "A" document defining the general state of the art which is not considered to be of		«I"	"I" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention				
particular relevance  "X"  document of particular relevance; the claimed invention cannomics of cannot be considered to involve an invention cannomics when the document is taken alone							
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)		чY"	document of particular relevance; the cl- considered to involve an inventive step with one or more other such documents,	when the document is combined			
	t referring to an oral disclosure, use, exhibition or other means	اري سيميا	to a person skilled in the set	mily			
	t published prior to the international filing date but later than the late claimed		document member of the same patent fa				
Date of the actual completion of the international search			Date of mailing of the international search report				
07 July 2005 (07:07:2005) -		02 SEP ZUU3					
	ailing address of the ISA/US	Author	rized officer	2/1/10			
Mail Stop PCT, Attn: ISA/US Commissioner for Patents		AR Salimi.					
DO D1460			none No. (571) 272-1600				
Facsimile No. (703) 305-3230							
Form PCT/ISA/210 (second sheet) (January 2004)							

International application No.

PCT/US04/38050

Box No. I Nucleotide and/or amino acid sequence(s) (Continuation of item 1.b of the first sheet)					
inventi	egard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed ton, the international search was carried out on the basis of type of material  a sequence listing  table(s) related to the sequence listing				
ъ.	format of material in written format in computer readable form				
c.	time of filing/furnishing  contained in the international application as filed  filed together with the international application in computer readable form  furnished subsequently to this Authority for the purposes of search				
2.	In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.				
3.	Additional comments:				
2					

International application No.
PCT/US04/38050

	No. II	Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)
This	nternatio	mal search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1.		Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
2.		Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3.		Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Вох	No. III	Observations where unity of invention is lacking (Continuation of item 3 of first sheet)
This Plea	Internation See See Co	As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.	nark on	
1		No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet(2)) (January 2004)

International application No. PCT/US04/38050

## BOX III. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Group I, claim(s) 1-30, drawn to a method of screening an agent for activity in modulating T lymphocyte function, wherein cells express HSV Us3 polypeptide.

Group II, claim(s) 31-33, drawn to a method of screening an agent for activity in modulating T lymphocyte function, wherein cells are infected with HSV.

Group III, claim(s) 34, drawn to method for blocking suppression of cytotoxic T cell activity.

Group IV, claim(s) 35, drawn to method of suppressing cytotoxic T cell activity against target antigen.

Group V, claim(s) 36, drawn to method of screening an agent for activity in suppressing Y lymphocyte function.

The inventions listed as Groups I-V do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: The invention of Group I is known in the prior art as evidence by MUNGER et al (US 2003/0171279 A1, September 11, 2003) wherein the reference teaches a method of screening an agent for activity of T lymphocyte wherein a cell expressing a HSV Us3 polypeptide (see all the claims especially Claims 50-71). The cited evidence proves that the technical feature of Group I does not make a contribution over the prior art. Thus, the claims are not so linked by a special technical feature within the meaning of PCT Rule 13.2.

International application No. PCT/US04/38050

Continuation of B. FIELDS SEARCHED Item 3: WEST, DERWENT, EPA, JPA, MEDLINE, BIOSIS, NPL
Herpesvirus, apoptosis, BAD, pre-apoptosis,